Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis

ABSTRACT

BACKGROUND:

Considering the disruptions imposed by lockdowns and social distancing recommendations, coupled with overwhelmed healthcare systems, researchers worldwide have been exploring drug repositioning strategies for treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

OBJECTIVE:

To compile results from randomized clinical trials on the effect of dexamethasone, compared with standard treatment for management of SARS-CoV-2.

DESIGN AND SETTING:

We conducted a systematic review and meta-analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines in a Brazilian public university.

METHODS:

We sought to compile data from 6724 hospitalized patients with confirmed or suspected SARS-CoV-2 infection.

RESULTS:

Treatment with dexamethasone significantly reduced mortality within 28 days (risk ratio, RR: 0.89; 95% confidence interval, CI: 0.82-0.97). Dexamethasone use was linked with being discharged alive within 28 days (odds ratio, OR: 1.20; 95% CI: 1.07-1.33).

CONCLUSIONS:

This study suggests that dexamethasone may significantly improve the outcome among hospitalized patients with SARS-CoV-2 infection and associated severe respiratory complications. ­Further studies need to consider both dose-dependent administration and outcomes in early and later stages of the disease.

PROSPERO platform:

CRD42021229825.

KEYWORDS (MeSH terms):
Dexamethasone; COVID-19; SARS-CoV-2; Meta-analysis [publication type]; Pulmonary medicine

AUTHORS’ KEYWORDS:
Coronavirus pandemic; Drug repurposing; Respiratory medicine; Clinical trials

INTRODUCTION

By June 23, 2021, the coronavirus pandemic had reached 192 countries and regions with > 179 million and > 3.8 million confirmed cases and deaths, respectively.¹ The Coronaviridae Study Group classified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within the family Coronaviridae, suborder Cornidovirineae, order Nidovirales.²

Given the disruption caused by lockdowns and social distancing, as well as overburdened healthcare systems, researchers are investigating different strategies for treating SARS-CoV-2 infections and are exploring drug repurposing.³ The World Health Organization Solidarity Trial report showed that treatments with drugs such as remdesivir, hydroxychloroquine, lopinavir and interferon had either little or no impact on mortality, need for intubation or overall hospital stay.⁴ On the other hand, corticosteroids (especially dexamethasone) might be beneficial for treating the SARS-CoV-2-induced cytokine storm.⁵ Data from the Recovery Trial noted that dexamethasone significantly reduced SARS-CoV-2-related deaths (by around 30% among patients receiving mechanical ventilation and by around 20% among those receiving oxygen alone).⁶ Therefore, several randomized controlled trials (RCTs) are underway to assess the effect of dexamethasone with regard to treatment of SARS-CoV-2 infection.

OBJECTIVE

We sought to synthesize the evidence from randomized controlled trials (RCTs) on the clinical relevance of dexamethasone, compared with standard treatment, among hospitalized SARS-CoV-2 patients.

METHODS

This study followed the guidelines for obtaining up-to-date and qualified biomedical literature.⁷ The review was registered on the PROSPERO platform (CRD42021229825). The inclusion criteria were that the studies needed to be RCTs that addressed hospitalized patients with confirmed or suspected ­SARS-CoV-2 infection, as reported in each study, either published or accepted for publication after the peer review. Other types of research designs, such as cross-sectional studies, as well as editorials, letters, reviews and study protocols, constituted exclusion criteria.

We independently searched the PubMed and Embase databases for RCTs. Publications were retrieved up to a cutoff date of February 14, 2021. The following MeSH terms were used: “coronavirus” OR “COVID-19” OR “2019-nCoV” OR “SARS-CoV-2” OR “severe acute respiratory syndrome” OR “SARS” AND “dexamethasone” AND “randomized controlled trial” or “randomized clinical trial”. Three experienced researchers (G.A., L.E.F. and J.P.X.) performed the searches and reviewed the abstracts. Each investigator independently selected studies for further inclusion, based on inclusion and exclusion criteria. The initial search returned 32 results from Embase and 193 from PubMed. After removing editorials, letters, reviews, protocols, duplicates and observational studies, two RCTs were found to fully satisfy our inclusion criteria (Appendix 1). These were found in Embase^8,9 and PubMed.⁹ There were no disagreements between the review authors regarding the inclusion criteria. For each RCT, sample details, covariates analyzed, dosage and duration of dexamethasone treatment were extracted. The primary outcome measured was the risk ratio (RR) for death at 28 days and the secondary outcome was the odds ratio (OR) of being discharged alive within 28 days. In addition, these trials were assessed for potential risk of bias.¹⁰

RESULTS

Data were extracted by D.S. and G.W. and were analyzed using RevMan 5.4.¹¹ Through using the Cochrane Collaboration’s tool for assessing risk of bias in randomized trials, these two authors concluded that both of the RCTs included had low risk of bias, with the exception of the item “blinding of participants and staff”.¹⁰ To test the effect of dexamethasone on mortality, we obtained the RR from these two RCTs, which included 6724 patients. The results indicated that treatment with dexamethasone significantly reduced mortality within 28 days (RR = 0.89; 95% CI: 0.82, 0.97; I² = 0%; Figure 1A). The effect of dexamethasone on the odds of being discharged alive within 28 days was significant (OR = 1.20; 95% CI: 1.07, 1.33; I² = 63%; Figure 1B).^8,9

Figure 1.
Risk ratio for dexamethasone with regard to mortality (A) and odds ratio for being discharged alive (B), among individuals with SARS-CoV-2 infection.

Horby et al.⁸ published results from 6425 hospitalized patients (mean age = 66.1 ± 15.7 years; 36% female) who were admitted between March and June 2020 at 176 healthcare institutions in the United Kingdom with confirmed (~88%) or suspected SARS-CoV-2 infection (~10-12%). Most of the sample (56%) had preexisting diseases, among which at least one in five had diabetes, heart disease or chronic lung disease. Both the healthcare workers and the patients were aware of the treatment status. A 2:1 ratio with regard to receiving standard care (n = 4321) or standard care plus dexamethasone was adopted (n = 2104). Dexamethasone (6 mg) was administered orally or intravenously once daily for up to ten days. Mortality at 28 days was significantly lower in the intervention group (22.9%) than in the usual care group (25.7%). Deaths were lower in the interventions among patients receiving invasive mechanical ventilation (29.3% versus 41.4%) and among those receiving oxygen only (23.3% versus 26.2%). The effect of dexamethasone on mortality was not statistically significant among patients who did not receive any respiratory support at randomization. Hospitalization was shorter in the intervention group (median = 12 days) than in the usual care group (median = 13 days). The intervention group had a risk ratio of 1.10 with regard to being discharged alive within 28 days, and the largest effect in this regard was reported among patients who were receiving invasive mechanical ventilation at the time of randomization.⁸

Tomazini et al.⁹ reported results from 299 hospitalized patients with confirmed (> 95%) or suspected SARS-CoV-2 infection (mean age = 61 ± 14.0 years; 37% female). The most frequent underlying health condition was hypertension, in both groups (over 60%), followed by diabetes (over 37%). Recruitment take place between April and June 2020 at 41 intensive care units (ICUs) in Brazil. Both the healthcare workers and the patients were aware of the treatment status. A 1:1 ratio for receiving standard care (n = 148) or standard care plus dexamethasone was adopted. Dexamethasone was administered intravenously at a dosage of 20 mg daily for five days, and then 10 mg once daily for an additional five days or until discharge from the intensive care unit. In contrast to Horby et al.,⁸ the primary outcome was ventilator-free days within the first 28 days. The covariates included demographic and physiological data, history of corticosteroid use and time elapsed since symptom onset, among other related data. A higher number of ventilator-free days in the intervention group (6.6 days), in comparison with the standard treatment (4.0 days) within the first 28 days of treatment, was reported as the primary outcome. Mortality at 28 days was lower in the dexamethasone group (56.3%), compared with standard treatment (61.5%), although the differences were not statistically significant. In terms of length of hospital stay, the intervention group had an odds ratio (OR) of 1.90 of being discharged alive within 28 days (27.8% [dexamethasone] versus 16.9% [standard care]).⁹

DISCUSSION

The results from this investigation showed that treatment with dexamethasone had a positive impact on mortality and length of hospitalization among SARS-CoV-2 hospitalized patients. However, the two RCTs assessed used different doses of the drug and both primary and secondary outcomes varied between the studies.^8,9 Consequently, these data must be interpreted as preliminary at this stage and further RCTs are needed in order to obtain an accurate perspective regarding the role and regimen of dexamethasone for treating patients with mild, moderate and severe SARS-CoV-2 infection.

Currently, there are 64 clinical studies registered at ClinicalTrials.gov, which are at different phases and are being conducted in many regions of the world. Hopefully, these results could help immensely in clarifying the protocols that should be adopted for use of dexamethasone for treating SARS-CoV-2 infection.¹⁵

Although the safety of this drug has been demonstrated in relation to other infectious diseases, such as viral pneumonia,^16,17 the risks from using corticosteroids among patients with mild to severe symptoms, including acute respiratory distress syndrome (ARDS) caused by SARS-CoV-2 infection,^18,19 remain unclear.

In severe SARS-CoV-2 infection, the immunopathological responses appear to partially determine the outcome, which would explain why Horby et al.⁸ found specific effects in these cases. Early administration of glucocorticoids may impair antiviral activity. Another mechanism possibly related to shorter hospital stays and higher survival rates is the potential of dexamethasone for preventing pulmonary fibrosis in COVID-19 patients and in patients with ARDS that was not caused by SARS-CoV-2 (i.e. sepsis, trauma-induced shock and other viral infections).^13-14

Importantly, the intervention group of Tomazini et al.⁹ was receiving concomitant treatment with other drugs such as hydroxychloroquine (23.8%) and azithromycin (69.9%), while Horby et al.⁸ adopted a 2:1 randomization methodology, thus raising some concerns regarding statistical power.²⁰ Future studies will need to address these limitations through examining dose-dependent administration of dexamethasone in early and later stages of COVID-19 disease, taking into account the confounding effects of other medications and comorbidities.

CONCLUSION

Through combining the evidence, healthcare professionals dealing with the current pandemic can be provided with relevant information, especially in countries where waves of SARS-CoV-2 infection are recurrent. This study suggests that use of dexamethasone could significantly improve the outcomes among critically ill patients with SARS-CoV-2 infection and associated severe respiratory complications.

REFERENCES

• ¹
  Center for Systems Science and Engineering, Johns Hopkins University. COVID-19 dashboard [Internet]. 2021. Available from: Available from: https://coronavirus.jhu.edu/map.html Accessed in 2021 (Jun 23).
  » https://coronavirus.jhu.edu/map.html
• ²
  Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5(4):536-44. PMID: 32123347; https://doi.org/10.1038/s41564-020-0695-z.
  » https://doi.org/https://doi.org/10.1038/s41564-020-0695-z
• ³
  Campbell CM, Guha A, Haque T, Neilan TG, Addison D. Repurposing immunomodulatory therapies against coronavirus disease 2019 (Covid-19) in the era of cardiac vigilance: a systematic review. J Clin Med. 2020;9(9):2935. PMID: 32932930; https://doi.org/10.3390/jcm9092935.
  » https://doi.org/https://doi.org/10.3390/jcm9092935
• ⁴
  WHO Solidarity trial consortium. Repurposed antiviral drugs for COVID-19 - interim WHO SOLIDARITY trial results [Internet]. Infectious Diseases (except HIV/AIDS); 2020. Available from: Available from: http://medrxiv.org/lookup/doi/10.1101/2020.10.15.20209817 Accessed in 2021 (Jan 6).
  » http://medrxiv.org/lookup/doi/10.1101/2020.10.15.20209817
• ⁵
  Sharun K, Tiwari R, Dhama J, Dhama K. Dexamethasone to combat cytokine storm in COVID-19: Clinical trials and preliminary evidence. Int J Surg. 2020;82:179-81. PMID: 32896649; https://doi.org/10.1016/j.ijsu.2020.08.038.
  » https://doi.org/https://doi.org/10.1016/j.ijsu.2020.08.038
• ⁶
  Ortolani C, Pastorello EA. Hydroxychloroquine and dexamethasone in COVID-19: Who won and who lost? Clin Mol Allergy [Internet]. 2020;18(1). Available from: Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L632824311&from=export Accessed in 2021 (Feb 14).
  » https://www.embase.com/search/results?subaction=viewrecord&id=L632824311&from=export
• ⁷
  Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8(5):336-41.
• ⁸
  Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med [Internet]. 2020. Available from: Available from: https://www.embase.com/search/results?subaction=viewrecord&id=L632383122&from=export Accessed in 2021 (Feb 14).
  » https://www.embase.com/search/results?subaction=viewrecord&id=L632383122&from=export
• ⁹
  Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020;324(13):1307-16. PMID: 32876695; https://doi.org/10.1001/jama.2020.17021.
  » https://doi.org/https://doi.org/10.1001/jama.2020.17021
• ¹⁰
  Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. PMID: 22008217; https://doi.org/10.1136/bmj.d5928.
  » https://doi.org/https://doi.org/10.1136/bmj.d5928
• ¹²
  Nordic Cochrane Centre, Cochrane Collaboration. Review Manager (RevMan) [Computer program]. Version 5.4. 2020.
• ¹³
  Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019 Mar 14;5(1):1-22. PMID: 30872586; http://doi.org/10.1038/s41572-019-0069-0.
  » https://doi.org/http://doi.org/10.1038/s41572-019-0069-0
• ¹⁴
  Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Resp Med. 2019; 8(12):1233-44. PMID: 33075298; http://doi.org/10.1016/S2213-2600(20)30404-5.
  » https://doi.org/http://doi.org/10.1016/S2213-2600(20)30404-5
• ¹⁵
  U. S. National Library of Medicine. Clinical Trials [Internet]. Bethesda: Clinical Trials; 2021 [cited 2021 Jun 22]. Available from: Available from: https://clinicaltrials.gov/ct2/results?term=dexamethasone&cond=Covid19 Accessed in 2021 (Jul 12).
  » https://clinicaltrials.gov/ct2/results?term=dexamethasone&cond=Covid19
• ¹⁶
  Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020 ;8(3):267-76. PMID: 32043986; https://doi.org/10.1016/S2213-2600(19)30417-5.
  » https://doi.org/https://doi.org/10.1016/S2213-2600(19)30417-5
• ¹⁷
  Ye Z, Wang Y, Colunga-Lozano LE, et al. Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis. CMAJ. 2020;192(27):E756-67. PMID:32409522; https://doi.org/10.1503/cmaj.200645.
  » https://doi.org/https://doi.org/10.1503/cmaj.200645
• ¹⁸
  The National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006;354:1671-84. PMID: 16625008; https://doi.org/10.1056/NEJMoa051693.
  » https://doi.org/https://doi.org/10.1056/NEJMoa051693
• ¹⁹
  Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Shen Lim W. Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. Crit Care Med. 2020; 48(2):e98-106. PMID: 31939808; https://doi.org/10.1097/CCM.0000000000004093.
  » https://doi.org/https://doi.org/10.1097/CCM.0000000000004093
• ²⁰
  Kelleni MT. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment. SN Compr Clin Med. 2021; 3: 919-923. PMID: 33644693; https://doi.org/10.1007/s42399-021-00824-4.
  » https://doi.org/https://doi.org/10.1007/s42399-021-00824-4

• 1
  Centro de Ciências da Saúde (CCS), Universidade Estadual do Oeste do Paraná (UNIOESTE), Francisco Beltrão (PR), Brazil; and Faculdade de Medicina de Ribeirão Preto (FMRP), Universidade de São Paulo (USP), Ribeirão Preto (SP), Brazil

• Sources of funding: None

Appendix 1. Prisma Flow Diagram.

Publication Dates

• Publication in this collection
  11 Oct 2021
• Date of issue
  2021

History

• Reviewed
  27 Feb 2021
• Received
  23 June 2021
• Accepted
  30 June 2021